C07J 7/003
By a saturated or unsaturated hydrocarbon group
Official title: {by a saturated or unsaturated hydrocarbon group}
C07J7/003 (By a saturated or unsaturated hydrocarbon group) appears on 18 US grants and 9 published applications in this corpus.
Search patents in C07J- Granted patents
- 18
- Published applications
- 9
- Assignees
- 12
- Inventors
- 56
- Latest grant
- 28 May 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 0 | 0 |
| 1979 | 1 | 0 |
| 1980 | 2 | 0 |
| 1981 | 0 | 0 |
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 2 | 0 |
| 1986 | 2 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 1 |
| 2016 | 0 | 1 |
| 2017 | 1 | 0 |
| 2018 | 0 | 0 |
| 2019 | 1 | 1 |
| 2020 | 0 | 1 |
| 2021 | 0 | 0 |
| 2022 | 0 | 2 |
| 2023 | 0 | 1 |
| 2024 | 1 | 0 |
| 2025 | 0 | 2 |
By publication year. Applications have been published since 2001.
Recent patents
- C7, C12, and C16 substituted neuroactive steroids and their methods of use28 May 2024US 11,993,628 B2Sage Therapeutics, Inc.
- Non-hormonal steroid modulators of NF-κβ for treatment of disease5 Nov 2019US 10,464,967 B2ReveraGen BioPharma, Inc.
- Combination of estrogens plus antiprogestins with significant partial agonistic effect as an effective treatment of menopausal symptoms and for prevention of the occurrence of breast cancer26 Dec 2017US 9,850,273 B2Evestra, Inc.
- Methylation or ethylation agent and process for 1,4-addition of a methyl or ethyl group to an .alpha., .beta.-unsaturated keto compound1 Jun 1999US 5,908,944 ASchering Corporation
- Substituted 4-aza-5.alpha.-androstan-ones as 5.alpha.-reductase inhibitors2 Dec 1997US 5,693,809 AMerck & Co., Inc.
- Non-hormonal steroid modulators of nf-kappa beta for treatment of disease8 May 2025US 2025/0145657 A1ReveraGen BioPharma, Inc.
- C7, c12, and c16 substituted neuroactive steroids and their methods of use20 Mar 2025US 2025/0092084 A1Sage Therapeutics, Inc.
- C7, c12, and c16 substituted neuroactive steroids and their methods of use19 Jan 2023US 2023/0021308 A9Sage Therapeutics, Inc.
- Non-hormonal steroid modulators of nf-kappa beta for treatment of disease13 Oct 2022US 2022/0324902 A1ReveraGen BioPharma, Inc.
- C7, c12, and c16 substituted neuroactive steroids and their methods of use6 Jan 2022US 2022/0002340 A1Sage Therapeutics, Inc.
Most cited
By later US patents
- Chemical compounds60US 4,192,871 AGlaxo Laboratories Limited · 1980
- 3-Keto-19-nor-.DELTA.4,9-steroids39US 4,477,445 ARoussel Uclaf · 1984
- 5 .alpha.-pregnan-20-ones and 5-pregnen-20-ones and related compounds24US 5,175,154 AResearch Corporation Technologies, Inc. · 1992
- 3-Keto-19-nor-.DELTA..sup.4,9 -steroids22US 4,540,686 ARoussel Uclaf · 1985
- Novel 3-keto-19-nor-.DELTA..sup.4,9 -steroids15US 5,064,822 ARoussel Uclaf · 1991